Current Advances of Liquid Biopsies in Prostate Cancer with Dr. Posadas

1 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Edwin M. Posadas, MD, FACP, Director of the Experimental Therapeutics Program and the Medical Director of the Center for Uro-Oncology Research Excellence / Urologic Oncology Disease Research Group at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, explores advancements in prostate cancer diagnostics and treatment. In this 15-minute presentation, Dr. Posadas emphasizes the evolving role of biomarkers and liquid biopsy technologies in prostate cancer management.

Dr. Posadas shares that liquid biopsies, particularly cell-free DNA (cfDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs), are emerging as valuable tools in tracking disease progression and treatment response. Data highlights cfDNA’s role in guiding treatment decisions. CTCs provide additional insights, with research demonstrating their ability to reflect tumor biology, including molecular changes in metastatic progression.

Dr. Posadas emphasizes integrating liquid biopsy data with molecular imaging to improve precision treatment strategies. Liquid biopsies offer cost-effective and accessible insights, and their adoption could complement existing imaging techniques, especially in detecting treatment resistance.
Category
Urology
Be the first to comment

Up Next